Fundamental Data for IDEV

INDEVUS PH(NSDQ:IDEV)

Indevus Pharmaceuticals is engaged in the development and commercialization of a portfolio of products and product candidates, including multiple compounds in late-stage clinical development.

# Employees: 246

Address: 33 Hayden Avenue,Lexington,MA,USA

Phone: 781 861-8444

Fax: 781 861-3830

Website: www.interneuron.com

Email: RDeCarlo@indevus.com

Sector: Medical

Industry: MED-DRUGS

Executive Officers

Glenn L. Cooper M.D. (Chmn.; C.E.O.)

Dale Ritter (Sr. V.P.; Fin.)

Michael W. Rogers (Exec. V.P.; C.F.O.; Treas.)

Mark S. Butler (Exec. V.P.; Chief Admin. Off..; GenlL. Counsel)

Bobby W. Sandage Jr. (Exec. V.P. Research & Devp.; Chief Scient. Off.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 12/31/2008

Next Earnings Date(Expected): 4/22/2009

Mean EPS (Next Qtr): ($0.10)

Mean EPS (Year): ($0.44)

Mean Estimate(Long Term): $20.00

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 3

Shares Performance

Period	IDEV	Compare to S&P
YTD	-0.01 %	124.58 %
4 Weeks	-0.01 %	-0.01 %
12 Weeks	-0.01 %	-0.01 %

Shares Information

Analyst Coverage: Y

Avg Volume: 1205334

Shares Outstanding: 78M

Market Cap: ($0.01)M

52 Week High: $6.11

52 Week Low: $1.26

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 11/30/1989 IDEV split by factor of 1.200

Earnings Performance

EPS Growth in Last Quarter: 44.44 %

EPS Growth in Last Year: 47.37 %

Sales Growth in Last Quarter: 13.15 %

Sales Growth in Last Quarter: 60.98 %

Financials

Qtr Book Value: ($0.01)

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: -0.010